Ian Gordon
Surgical · Oklahoma City, OKNPI 1770906539
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 900 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 900 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Otsuka America Pharmaceutical, Inc.$992
- Axsome Therapeutics, Inc.$881
- Ironshore Pharmaceuticals Inc.$765
- plus $7K from 28 others
What the payments were for
- Food & beverage$14,040100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 180 | $2,278 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 70 | $1,187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $1,123 |
| Otsuka America Pharmaceutical, Inc. | 79 | $992 |
| Axsome Therapeutics, Inc. | 62 | $881 |
| Ironshore Pharmaceuticals Inc. | 41 | $765 |
| Noven Therapeutics, LLC | 59 | $735 |
| Bausch Health US, LLC | 36 | $653 |
| Lundbeck LLC | 37 | $622 |
| Neurocrine Biosciences, Inc. | 39 | $607 |
| Johnson & Johnson | 33 | $561 |
| Corium, LLC | 30 | $539 |
| Supernus Pharmaceuticals, Inc. | 22 | $520 |
| Alkermes, Inc. | 25 | $514 |
| Sunovion Pharmaceuticals Inc. | 14 | $295 |
| Merck | 16 | $273 |
| Vanda Pharmaceuticals Inc. | 11 | $213 |
| Teva Pharmaceuticals USA, Inc. | 11 | $206 |
| Avanir Pharmaceuticals, Inc. | 11 | $168 |
| Jazz Pharmaceuticals Inc. | 8 | $158 |
| Eisai Inc. | 9 | $152 |
| Idorsia Pharmaceuticals US Inc | 8 | $146 |
| Indivior Inc. | 7 | $121 |
| Tris Pharma Inc | 5 | $85 |
| Adlon Therapeutics L.p. | 4 | $57 |
| Lilly USA, LLC | 2 | $46 |
| Orexo US, Inc. | 2 | $34 |
| Neos Therapeutics, LP | 1 | $23 |
| Almatica Pharma LLC | 1 | $22 |
| Braeburn Inc. | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Harmony Biosciences LLC | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$173
How this compares
$14,058 in reported general payments places this provider in the 95th percentile of 94 surgical providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $20,116 |
| Doxepin Hcl | 20 | $4,137 |
| Bupropion XlBupropion Hcl | 18 | $1,064 |
| Lamotrigine | 16 | $467 |
| Eszopiclone | 36 | $451 |
| Sertraline Hcl | 19 | $435 |
| Trazodone Hcl | 36 | $330 |
| Quetiapine Fumarate | 14 | $231 |
| Zolpidem Tartrate | 12 | $124 |
| Escitalopram Oxalate | 11 | $68 |
| Alprazolam | 12 | $7 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,278 | $20,11612 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $43519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 surgical providers in Oklahoma.
Other surgical in Oklahoma City
- Kayla HaleOklahoma City$36K
- Randall PapeOklahoma City$25K
- Eduardo GarciaOklahoma City$4K
- Lauren HinkOklahoma City$3K
- Nathan CharltonOklahoma City$2K
- Stephanie GarrisonOklahoma City$2K
- Katrina StewartOklahoma City$2K
- Elizabeth LittleOklahoma City$849
- Dustin WagnerOklahoma City$837
- Kristin StrongOklahoma City$781
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.